Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763031 | 0.80 | KDM1A (0.45) | — | |
| SCHEMBL15425042 | 0.78 | TACR1 (0.48) | MAPTTACR1S1PR1TYRATM | |
| SCHEMBL13259431 | 0.74 | TACR1 (0.52) | MAPTTDP1TACR1POLBCTSL | |
| SCHEMBL15423917 | 0.74 | ALDH1A1 (0.44) | MAPTTDP1ATMALDH1A1MAPK1 | |
| SCHEMBL4691605 | 0.69 | ALDH1A1 (0.60) | TDP1ALDH1A1MAPK1 | |
| SCHEMBL25013937 | 0.68 | SMN1; SMN2 (0.51) | ATMNAMPTPOLB | |
| SCHEMBL825025 | 0.66 | MIF (0.39) | MAPTS1PR1ATMALDH1A1MAPK1 | |
| SCHEMBL3338015 | 0.64 | MAPT (0.49) | MAPTS1PR1TYRATMS1PR4 | |
| SCHEMBL11367046 | 0.64 | TACR1 (0.54) | MAPTTACR1S1PR1POLBCTSL | |
| SCHEMBL10420650 | 0.63 | TACR1 (0.57) | MAPTTDP1TACR1S1PR1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143301-B2 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
| WO-2010039793-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MAPT 4065/4885TDP1 3331/4885TACR1 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.